Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Status:
Completed
Trial end date:
2018-12-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of dabrafenib and pazopanib
hydrochloride when given together in treating patients with advanced malignant tumors.
Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth